Philip Bejon/Vaccine

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye, D. T. Mensah, V. A. Murungi, L. M. Nkumama, I. Nebie, I. Marsh, K. Cisse, B. Bejon, P. Osier, F. H. Sirima, S. B. Mvvc Infant Immunology Study Group
Vaccine, (2016). 34:160-6

A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Murungi, L. M. Kamuyu, G. Lowe, B. Bejon, P. Theisen, M. Kinyanjui, S. M. Marsh, K. Osier, F. H.
Vaccine, (2013). 31:3936-42

Response to "Poor control vaccines in two randomised trials of malaria vaccine?".Bejon, P. Abdulla, S. Lusingu, J. Olotu, A. Leach, A. Lievens, M. Tanner, M. von Seidlein, L.
Vaccine, (2009). 27:4745-6

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.Dudareva, M. Andrews, L. Gilbert, S. C. Bejon, P. Marsh, K. Mwacharo, J. Kai, O. Nicosia, A. Hill, A. V.
Vaccine, (2009). 27:3501-4

Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.Agak, G. W. Bejon, P. Fegan, G. Gicheru, N. Villard, V. Kajava, A. V. Marsh, K. Corradin, G.
Vaccine, (2008). 26:1963-71

Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria.Bejon, P. Mwangi, T. Lowe, B. Peshu, N. Hill, A. V. Marsh, K.
Vaccine, (2007). 25:8198-202

Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.Bejon, P. Mwacharo, J. Kai, O. K. Todryk, S. Keating, S. Lang, T. Gilbert, S. C. Peshu, N. Marsh, K. Hill, A. V.
Vaccine, (2006). 24:4709-15